EP2 antagonist compounds

A compound having the structure of Formula (II):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 and R2 are each independently hydrogen, deuterium, halogen, or C1-4 alkyl;
• R3 and R4 are each independently hydrogen, deuterium, halogen, or C1-4 alkyl;
• R5 and R6 are each independently hydrogen, deuterium, halogen, or C1-4 alkyl;
• or R5 and R6 are taken together with the carbon atom to which they are attached to form an oxetane;
• R7 and R8 are each independently hydrogen, deuterium, halogen, —CN, —C1-4 alkyl, —C1-4 haloalkyl, —OH, —O(C1-4 alkyl), —O(C1-4 haloalkyl), —NH2, —NH(C1-4 alkyl), —N(C1-4 alkyl)2, —(C1-4 alkyl)O(C1-4 alkyl), —C(O)OH, —C(O)O(C1-4 alkyl), —C(O)NH2, —C(O)NH(C1-4 alkyl), —C(O)N(C1-4 alkyl)2, substituted or unsubstituted C3-6 cycloalkyl, or substituted or unsubstituted 3- to 6-membered heterocycloalkyl;
• or R7 and R8 are taken together with the carbon atom to which they are attached to form a cyclopropane or an oxetane;
• R9 and R10 are each independently hydrogen, deuterium, halogen, or C1-4 alkyl;
• or R9 and R10 are taken together with the carbon atom to which they are attached to form an oxetane;
• RA1 is halogen, C1-4 alkyl, or cyclopropyl;
• and
• RA2 is hydrogen, deuterium, halogen, or optionally deuterated or halogenated methyl;
• each RB is independently selected from the group consisting of halogen, —CN, —C1-4 alkyl, —C1-4 haloalkyl, —C1-4 aminoalkyl, —C1-4 hydroxyalkyl, —C1-4 methoxyalkyl, —(C1-4 alkyl)O(C1-4 alkyl), —C(O)(C1-4 alkyl), —C(O)OH, —C(O)O(C1-4 alkyl), —C(O)NH2, —C(O)NH(C1-4 alkyl), —C(O)N(C1-4 alkyl)2, —NH2, —NH(C1-4 alkyl), —NH(C3-6 cycloalkyl), —NH(C3-6 heterocycloalkyl), —N(C1-4 alkyl)2, —NHC(O)C1-4 alkyl, —NHC(O)O(C1-4 alkyl), —NHS(O)2C1-4 alkyl, —OH, —O(C1-4 alkyl), —O(C1-4 haloalkyl), —SH, —S(C1-4 alkyl), —S(O)(C1-4 alkyl), —S(O)(NH)(C1-4 alkyl), —S(O)2(C1-4 alkyl), —S(O)2NH2, —S(O2)NHCH3, substituted or unsubstituted C3-6 cycloalkyl, or substituted or unsubstituted 3- to 6-membered heterocyclyl;
• Ring C is bicyclic heterocycle having one or more nitrogen atoms;
• or Ring C is Ring C′;
• each RC is independently selected from the group consisting of halogen, —CN, —C1-4 alkyl, —C1-4 haloalkyl, —(C1-4 alkyl)O(C1-4 alkyl), —C(O)OH, —C(O)O(C1-4 alkyl), —C(O)NH2, —C(O)NH(C1-4 alkyl), —C(O)N(C1-4 alkyl)2, —NH2, —NH(C1-4 alkyl), —N(C1-4 alkyl)2, —OH, —O(C1-4 alkyl), —O(C1-4 haloalkyl), —S(C1-4 alkyl), —SO2C1-4 alkyl, —SO2NHC1-4 alkyl, substituted or unsubstituted C3-6 cycloalkyl, or substituted or unsubstituted 3- to 6-membered heterocyclyl;
• or two RC taken together form a carbonyl;
• m is 0 to 3;
• n is 1, 2 or 3;
• and
• Ring C′ is selected from the group consisting of: